cerca CERCA
Domenica 13 Giugno 2021
Aggiornato: 13:15
Temi caldi

disruptive treatment for AUB

Femtech startup OCON Healthcare announces last patient in phase IIa clinical study, evaluating its intrauterine drug delivery platform IUB™ SEAD™, a non-invasive treatment for abnormal uterine bleeding (AUB)

The trial assesses the safety and efficacy of the IUB™ SEAD™, a disruptive treatment for AUB. In this study, 50% of the participating patients have reached the End of the Study point, demonstrating a significant reduction in bleeding, avoiding the need to undergo invasive uterine ablation procedures or even a hysterectomy

ora in
Prima pagina
articoli
in Evidenza